The liver cirrhosis market comprises therapies targeted at treating liver cirrhosis or complications arising due to cirrhosis. Liver cirrhosis refers to scarring of the liver caused by long-term liver damage leading to the liver not functioning properly. It is often caused by alcoholism, hepatitis B & C infections, obesity and metabolic disorders.

Therapies used in treatment of Liver Cirrhosis Market include vaccines to prevent hepatitis infections, medication to treat complications like ascites, edema, bleeding varices and hepatorenal syndrome. Other treatments include nutritional supplements and liver transplantation for end-stage cirrhosis patients.

The Global liver cirrhosis market is estimated to be valued at USD 1.41 Billion in 2024 and is expected to reach USD 2.03 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

Key players operating in the liver cirrhosis market are F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., and Bristol-Myers Squibb Company. Significant focus on R&D of novel drug molecules for effective treatment and management of liver cirrhosis is driving growth of these players.

Prevalence of liver cirrhosis is continuously growing worldwide majorly due to rising alcohol consumption and obesity levels. As per National Institute on Alcohol Abuse and Alcoholism, over 10 million people suffered from alcohol-related cirrhosis in 2020 in the US. This growing patient pool suffering from cirrhosis indicates high demand potential for liver cirrhosis drugs over the coming years.

Advancements in areas of drug delivery, regenerative medicines and liver transplantation techniques are also fueling growth of global liver cirrhosis therapeutics market. New drug formulations with better safety profile and improved patient compliance are being researched and developed.

Market Trends
Increased focus on development of combination therapy: Major companies are focusing on development of fixed dose combination therapies to target multiple aspects of cirrhotic pathophysiology like recurrent ascites, hepatic encephalopathy, and portal hypertension control.

Adoption of regenerative medicines: Researches evaluating potential of stem cell therapy, growth factors, and tissue engineering approaches for reversing cirrhosis or improving liver function are ongoing. Favorable outcomes can boost adoption of regenerative medicines.

Market Opportunities
Emerging economies in Asia: Developing nations like India and China with high prevalence of hepatitis and growing alcoholism represent lucrative opportunities. Increased access and awareness can drive future growth.

Orphan drug designation: Drugs targeting rare complications of cirrhosis like hepatopulmonary syndrome can be provided orphan drug status and tax incentives, attracting investments.

Impact of COVID-19 on Liver Cirrhosis Market Growth
The COVID-19 pandemic has significantly impacted the liver cirrhosis market. During the initial phase of the pandemic, the market witnessed decline in growth due to lockdowns imposed across various countries. This led to disruption in manufacturing and supply chain of drugs and medical devices used for treatment of liver cirrhosis. Furthermore, non-essential medical procedures and appointments were postponed which reduced the demand. People also avoided visiting hospitals and clinics for fear of getting infected by the virus.

However, post lockdowns as healthcare services gradually resumed, the market is witnessing steady growth again. With rising awareness, more number of people are getting tested and treated for liver disorders. This has propelled the demand for drugs and liver transplantation in recent times. Various government initiatives are also being undertaken to spread awareness about liver health and diseases. Telehealth and online consultations have picked up significantly helping people to seek medical advice without worrying about hospital visits.

The United States represents the largest geographical market for liver cirrhosis currently. This is attributed to high prevalence of non-alcoholic fatty liver disease (NAFLD) and alcohol abuse in the country. Availability of advanced healthcare infrastructure and widespread health insurance coverage further drives the market growth. However, China is expected to emerge as the fastest growing regional market in the coming years. This can be accredited to improving access to healthcare, rising research funding for liver diseases and growing focus of international companies on tapping opportunities in the country.
The COVID-19 pandemic has posed challenges for liver cirrhosis market globally but with resumption of normal activities and vaccination drives, the industry is likely to witness positive recovery going forward. Continued medical innovation, rapid adoption of telehealth and increasing public awareness about liver health will be crucial for sustained market growth post pandemic.

Get more insights on: Liver Cirrhosis Market

Get this Report in Japanese Language: 肝硬変市場

Get this Report in Korean Language: 간경변 시장        

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)